Skip to main content

Advertisement

Table 3 Measurement of PRDX2 autoantibody, PRDX3 autoantibody and their combination of VCA-IgA in NPC diagnosis

From: Serum proteomic-based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma

  AUC (95% CI) Sensitivity (%) Specificity (%) PPV (%) NPV (%) PLR NLR
NPC versus NC
 PRDX2 autoantibody 0.614 (0.542–0.686) 26.4 96.0 89.5 50.3 6.60 0.77
 PRDX3 autoantibody 0.600 (0.528–0.673) 24.5 95.0 86.3 49.4 4.90 0.79
 PRDX2 autoantibody + PRDX3 autoantibody 0.632 (0.561–0.703) 36.4 95.0 90.4 53.7 7.28 0.67
 VCA-IgA 0.719 (0.653–0.785) 48.8 95.0 92.6 59.0 9.76 0.54
 Autoantibody + VCA-IgA 0.811 (0.753–0.869) 66.7 95.0 94.5 68.9 13.34 0.35
Early-stage NPC versus NC
 PRDX2 autoantibody 0.642 (0.532–0.753) 27.5 96.0 73.4 76.8 6.88 0.76
 PRDX3 autoantibody 0.646 (0.537–0.755) 25.0 95.0 66.7 76.0 5.00 0.79
 PRDX2 autoantibody + PRDX3 autoantibody 0.664 (0.550–0.779) 40.0 95.0 76.2 79.8 8.00 0.63
 VCA-IgA 0.638 (0.528–0.747) 32.5 95.0 72.3 77.8 6.50 0.71
 Autoantibody + VCA-IgA 0.754 (0.652–0.857) 50.0 95.0 80.0 82.6 10.00 0.53
  1. AUC area under curve, 95% CI 95% exact confidence interval, NPC nasopharyngeal carcinoma, NC normal controls, PPV positive predictive value, NPV negative predictive value, PLR positive likelihood ratio, NLR negative likelihood ratio